Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?

被引：0
|
作者：
Chris Skedgel
Daniel Rayson
Tallal Younis
机构：
[1] University of East Anglia,Norwich Medical School
[2] Capital Health,Atlantic Clinical Cancer Research Unit
[3] Capital Health,Department of Medicine
来源：
Supportive Care in Cancer | 2016年 / 24卷
关键词：
Breast cancer; Febrile neutropenia; Granulocyte colony-stimulating factors; Economic evaluation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：387 / 394
页数：7
相关论文
共 50 条
  • [21] Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients
    Puertolas, Isabel
    Frutos Perez-Surio, Alberto
    Aranzazu Alcacera, Maria
    Andres, Raquel
    del Transito Salvador, Maria
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (03) : 315 - 321
  • [22] Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice
    Ahuva Averin
    Amanda Silvia
    Lois Lamerato
    Kathryn Richert-Boe
    Manpreet Kaur
    Devi Sundaresan
    Neel Shah
    Mark Hatfield
    Tatiana Lawrence
    Gary H. Lyman
    Derek Weycker
    Supportive Care in Cancer, 2021, 29 : 2179 - 2186
  • [23] Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients
    Isabel Puértolas
    Alberto Frutos Pérez-Surio
    María Aránzazu Alcácera
    Raquel Andrés
    María del Tránsito Salvador
    European Journal of Clinical Pharmacology, 2018, 74 : 315 - 321
  • [24] Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study
    Jolis, L.
    Carabantes, F.
    Pernas, S.
    Cantos, B.
    Lopez, A.
    Torres, P.
    Funes, C.
    Caballero, D.
    Benedit, P.
    Salar, A.
    EUROPEAN JOURNAL OF CANCER CARE, 2013, 22 (04) : 513 - 521
  • [25] Colony-stimulating factors: Clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia
    Raposo C.G.
    Marín Á.P.
    Barón M.G.
    Clinical and Translational Oncology, 2006, 8 (10) : 729 - 734
  • [26] The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials
    Wang, Li
    Baser, Onur
    Kutikova, Lucie
    Page, John H.
    Barron, Richard
    SUPPORTIVE CARE IN CANCER, 2015, 23 (11) : 3131 - 3140
  • [27] Efficacy of granulocyte colony stimulating factor as a secondary prophylaxis along with full-dose chemotherapy following a prior cycle of febrile neutropenia
    Gupta, Seema
    Singh, Pankaj K.
    Bhatt, Madan L. B.
    Pant, Mohan C.
    Gupta, Rajeev
    Negi, Mahendra P. S.
    BIOSCIENCE TRENDS, 2010, 4 (05) : 273 - 278
  • [28] Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
    Advani, S. H.
    Achreckar, Suvarna
    Thomas, Dennis
    Krishnankutty, Binny
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2010, 31 (03) : 79 - 82
  • [29] Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years
    Edelsberg, John
    Weycker, Derek
    Bensink, Mark
    Bowers, Charles
    Lyman, Gary H.
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (03) : 483 - 495
  • [30] Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer
    Gregory S. Calip
    Judith A. Malmgren
    Wan-Ju Lee
    Stephen M. Schwartz
    Henry G. Kaplan
    Breast Cancer Research and Treatment, 2015, 154 : 133 - 143
12345